LINDSAY DEMSEY: Open Payments
NPI 1992079883 · WINCHESTER, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,167 in 37 payments from 14 companies in 2025. Trend: 2023 $917 · 2024 $923 · 2025 $1,167
Food & beverage: $1,167
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 8 | $323 |
| UCB, Inc. | 8 | $237 |
| GENZYME CORPORATION | 2 | $153 |
| Novartis Pharmaceuticals Corporation | 4 | $118 |
| Lilly USA, LLC | 3 | $78 |
| Incyte Corporation | 3 | $55 |
| PFIZER INC. | 2 | $54 |
| Organon LLC | 1 | $28 |
| Amgen Inc. | 1 | $24 |
| LNHC, Inc | 1 | $24 |
Products named: TREMFYA, Bimzelx, DUPIXENT, OPZELURA, TALTZ, CIBINQO, Rhapsido, Otezla.
Industry payments across MA — which companies pay providers there.
